Real-world outcomes for relapsed or refractory multiple myeloma patients treated with lenalidomide and daratumumab sparing triplet regimens: a United States retrospective cohort study
Last Updated: Wednesday, January 10, 2024
With no singular standard of care for patients who are refractory to lenalidomide and daratumumab at time of relapse, this study describes the most frequent real-world use of treatment regimens that exclude these drugs in patients with early relapsed and/or refractory multiple myeloma. It also includes patient outcomes.
Advertisement
News & Literature Highlights